Skip to main content

Table 1 Metabolic characteristics of child survivors of acute lymphoblastic leukemia and lymphoma according to MS

From: Adipokines, insulin resistance, and adiposity as a predictors of metabolic syndrome in child survivors of lymphoma and acute lymphoblastic leukemia of a developing country

Variables

Firts Assessesment

After 6 months

All

No MS

MS

No MS

MS

n

52

45

7

42

10

Sex (M) n (%)

39

75

33

73

6

86

31

74

8

80

Current age (Y)a

12.1

(7.1, 17.0)

12.2

(7.1, 17.0)

11.1

(7.1, 17.1)

12.1

(7.1, 17.0)

11.6

(7.1, 17.1)

Age at cancer diagnosis (Y)a

5.3

(1.0, 13)

6

(0.8, 13.0)

4

(2, 11.1)

6.1

(2.1, 13.0)

4.1

(0.08, 12.1)

Time since completion of therapy (Y)a

4

(2, 5)

4

(2, 5)

4

(2, 5)

4

(2, 5)

4

(2, 5)

Diagnosis (n %)

 ALL

26

50

22

48.9

4

57.1

20

47.6

6

60.0

 Lymphoma

26

50

23

51.1

3

42.9

22

52.4

4

40.0

Pubertal stage (n %)

 1

33

63.5

28

62.2

5

71.4

18

42.9

7

70.0

 ≥ 2

19

36.5

17

37.8

2

28.6

24

57.1

3

30.0

Treatment recived (n %)

         

0.0

 Ch

35

67.3

31

68.9

4

57.1

28

66.7

7

70.0

 Ch + R

17

32.7

14

31.1

3

42.9

14

33.3

3

30.0

Nutritional Status (n %)

 Normal

29

55.8

28

62.2

1

14.3

27

64.3

0

0

 Overweight/Obesity

20

38.4

14

31.1

6

85.7

13

31.0

10

100

 Low weight

3

5.8

3

6.7

0

0

2

4.8

0

0

MS Components median (min, max)

 WC (cm)

70.5 (51.1, 105.7)

69.9 (51.1, 94.8)

78.1 (60.4, 105.7)*

50 (10, 100)

90 (90, 100)*

 SBP (pc)

47 (2, 99)

42.5 (2, 93)

58 (14, 99)

16 (1, 70)

65 (19, 95)*

 DBP (pc)

76 (15, 99)

75 (15, 97)

94 (19, 99)*

54 (11, 92)

94 (66, 99)*

 Triglicerydes (mg/dL)

96.6 (34, 231)

85 (34, 205)

182 (117, 231)*

80 (28, 259)

169 (104, 264)*

 HDL-C (mg/dL)

40 (18, 84)

40 (18, 84)

40 (18,46)

45 (20, 80)

37 (22, 68)

 Glucose (mg/dL)

89 (74, 116)

89 (74, 116)

93 (76, 112)

93 (77, 105)

90 (83, 115)

Others metabolic variables median (min, max)

 Insulin (μU/mL)

18.9 (4.3, 55)

18.7 (4.3, 55)

28.2 (17.5, 50)*

22.8 (3.4, 56.6)

31.5 (24.5, 64)*

 HOMA-IR

4.3 (0.79, 13.9)

4.2 (0.79, 12.7)

7.4 (3.3, 13.9)*

5.2 (0.68, 13.8)

7.3 (5.2, 15.4)*

 Adiponectin (μg/mL)

20.3 (1.3, 70)

23.4 (1.3, 70)

17.5 (11.7, 25.4)

20.2 (0.64, 57.3)

20.3 (8.3, 37.2)

 Adiponectin per Kg fat (μg/mL/kg)

1.4 (0.07, 8.0)

1.6 (0.07, 8.0)

1.0 (0.38, 3.9)*

1.7 (0.06, 14.3)

0.90 (0.27, 3.8)

 Leptin (ng/mL)

10.1 (1.2, 30.9)

8.0 (1.2, 30.9)

17.5 (8.5, 28.6)*

6.5, (1.1, 30.9)

22 (9.4, 28.2)*

 Leptin (μg/mL/kg)

0.69 (0.11, 3.9)

0.69 (0.11, 3.9)

1.0 (0.35, 3.7)

0.65 (0.11, 4.8)

1.0 (0.30, 4.2)

 Leptin to Adiponectin ratio

0.44 (0.06, 11)

0.35 (0.06, 11)

0.98 (0.69, 1.5)*

0.34 (0.05, 10.4)

1.1 (0.31, 1.7)*

 Body Fat (%)

29.9 (8.3, 46.7)

27.6 (8.3, 44.4)

38.3 (31.2, 46.7)*

25.5 (7.2, 45.5)

39.8 (29.6, 49.3)*

 VCAM (ng/mL)

925 (425, 1730)

930 (425, 1730)

769 (490, 1697)

753 (377, 2045)

683.9 (514, 1081)

 ICAM (ng/mL)

459 (254, 1079)

468 (254, 1079)

412 (325, 685)

456.5 (184, 137)

404 (199, 631)

  1. aValues are median (min, max); Abbreviations: MS Metabolic syndrome, Ch chemotherapy, Ch + R chemotheraphy + radiotherapy, HOMA-IR Homeostatic Model Assessment of Insulin Resistance, VCAM Vascular cell adhesion molecule, ICAM Intercellular adhesion molecule; Comparations were assessed using Mann–Whitney U-test due non-normal distribution of the data, and categorized data were analyzed using Fisher’s Test; * p value < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us